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Human T-cell leukemia viruses (HTLV-1 and HTLV-2) are
associated with a variety of human diseases, including
some severe ones. Transfusion transmission of HTLV
through cellular blood components is undeniable. HTLV
screening of blood donations became mandatory in
different countries to improve the safety of blood
supplies. In Japan and Europe, most HTLV-infected
donors are HTLV-1 positive, whereas in the United States
a higher prevalence of HTLV-2 is reported. Many
industrialized countries have also introduced universal
leukoreduction of blood components, and pathogen
inactivation technologies might be another effective
preventive strategy, especially if and when generalized to
all blood cellular products. Considering all measures
available to minimize HTLV blood transmission, the
question is what would be the most suitable and cost-
effective strategy to ensure a high level of blood safety
regarding these viruses, considering that there is no
solution that can be deemed optimal for all countries.
H
uman T-lymphotropic virus 1 (HTLV-1) and
human T-lymphotropic virus 2 (HTLV-2) are
retroviruses responsible for persistent human
infection but only rarely with severe clinical
manifestations.1,2 To date, although there has been no
conclusive evidence that HTLV-2 is an etiologic agent of
any specific disease, it has been associated to several
pathologies.3
As soon as they were discovered, it was clear that
HTLV-1 and HTLV-2 were transmitted by the transfusion
of cellular blood products.4 To date, the safety measures
are primarily based on donor suitability assessment and
leukoreduction of cellular blood components.5 Plasma
and plasma-derived medicinal products cannot transmit
these viruses. The introduction of routine screening of
blood donations for HTLV antibodies was motivated in
many countries, especially in Europe, by the need to pre-
vent HTLV-positive donations by donors from endemic
areas from entering the blood supply.
ABBREVIATIONS: ATL 5 adult T-cell leukemia; HAM/TSP 5
HTLV-associated myelopathy/tropical spastic paraparesis;
PRT(s) 5 pathogen reduction technology(-ies); QALY 5
quality-adjusted life-year; WB 5 Western blot; WP 5
window period.
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Pathogen reduction technologies (PRTs) offer a new
approach to increasing blood safety by actively or directly
targeting possible even emerging pathogens or donor
white blood cells (WBCs), but their use is still hampered
by the fact that none of the various technologies has so far
been applied to whole blood or red blood cells (RBCs).6
The aim of this review article is to analyze the role played
by HTLVs in transfusion medicine and to assess preven-
tive measures and their cost-effectiveness.
THE VIRUSES: CHARACTERISTICS AND
RELATED DISEASES
HTLV-1 and its congener HTLV-2 are retroviruses belonging
to the Deltaretrovirus genus of the subfamily Orthoretrovir-
inae.7 HTLV-1 was the first human retrovirus discovered in
1980 by Poiesz and others;8 2 years later, HTLV-2 infection
was documented for the first time.9 Seven different HTLV-1
subtypes exist, each endemic to a particular region.10,11
HTLV-2 is classified into four molecular subtypes each with
a specific geographic association.12
HTLV-1 and HTLV-2 show considerable homology in
terms of genome structure, replication pattern, and prop-
erties of the structural, regulatory, and accessory proteins.
Both viruses utilize the glucose transporter type 1 and
neuropilin-1 cellular receptors for their entry, although
only HTLV-1 is dependent on heparan sulfate proteogly-
cans.13 Still today, little is known about many aspects of
HTLV transmission. HTLV-1 mainly affects CD41 lympho-
cytes, while HTLV-2 predominantly affects CD81 lympho-
cytes albeit dendritic cells also carry proviruses. Although
cell-to-cell virus replication is “more efficient than cell-
free transmission,” recent insights suggest that the mech-
anism of transmission differs from the dogma that cell–
cell transmission of HTLV-1 only involves interaction
between T cells.14
HTLV-1 and HTLV-2 are very different in terms of
clinical impact. The majority of HTLV-1–infected individu-
als will remain asymptomatic and only a minority of them
develop disease. The two most common pathologies are
adult T-cell leukemia (ATL) and HTLV-associated myelop-
athy/tropical spastic paraparesis (HAM/TSP).15 Depend-
ing on ethnicity and sex, approximately 2% to 3%
of infected individuals develop ATL and 0.25% to 4%
develop HAM/TSP.3 Other associated pathologies include
neurologic diseases,16 uveitis,17 chronic inflammatory
arthropathy,18 infective dermatitis,19 Sj€ogren’s syndrome,20
polymyositis,21 bronchopneumopathy,22 and oral mani-
festations such as aphthous stomatitis, herpes labialis,
and nongenital warts.23 Most infected individuals remain
lifelong asymptomatic carriers and in some cases with
only cutaneous manifestations, thus confirming the
importance of anamnesis and physical examination of
blood donors with suspected infection.23,24 The mecha-
nisms by which HTLV-1 causes such different clinical pic-
tures are not understood and it is also not known why
disease typically occurs decades after initial infection and
affects less than 10% of carriers. Since no viral genotype
has been associated with any particular disease and there
is a large antiviral immune response, the currently
accepted hypothesis is that the host immune response is
the main determinant of the risk of disease.24
HTLV-2 has been linked to several cases of HAM/TSP
and to increased overall neurologic disability.25-27 Recent
data suggest that HTLV-1 and HTLV-2 carry similar risks in
terms of resulting in non-HAM neurologic illness. HTLV-2
may have an impact on platelet (PLT) count and be
responsible for infection with pneumonia, bronchitis,
arthritis, asthma, and dermatitis.28,29
THE DIAGNOSIS: TESTS AND
ALGORITHMS
The serologic diagnosis of the infection is based on an
enzyme immunoassay (EIA), which usually requires a
confirmation with immunoblot assays, namely, Western
blot (WB) or line immunoassays. The first screening tests
for the detection of HTLV-1 and -2 antibodies, introduced
in the mid-1980s, used HTLV-1 whole viral lysate as the
only antigen and had a poor HTLV-2 detection capacity.30
The new generations of assays recently released are based
on recombinant and/or synthetic peptide antigens alone
or in combination with viral lysate, include HTLV-2–
specific antigens and, therefore, have an improved sensi-
tivity for HTLV-2 antibody–positive specimens.30
Although these serologic screening assays generally
have a higher specificity than the earlier tests, they cannot
be accurate enough to distinguish one virus infection
from the other as some antibodies recognize both HTLV-1
and HTLV-2 antigens. In addition, they have a low positive
predictive value, especially in low-risk populations such
as blood donors. Therefore, all repeatedly reactive speci-
mens must be further tested to confirm the presence of
HTLV-1– and/or HTLV-2–specific antibodies.
WB is most frequently used for this purpose and com-
monly exploits HTLV-1 viral lysate, to which recombinant
envelope type-specific antigens can be added to improve
sensitivity and specificity for serologic confirmation of
HTLV-1 and HTLV-2 infections.30 Confirmatory testing
excludes HTLV infection in a high percentage of blood
donors who initially tested positive to EIA.31 The sample
will be considered seronegative if no reactivity to viral
antigens is observed with WB, indeterminate if there is
specific reactivity for HTLV antigens without fulfilling the
criterion for seropositivity, and seropositive if reactivity to
all antigens defined by the manufacturer as a positive pat-
tern is found.32
Usually, indeterminate WB profiles do not represent
true HTLV infection but, in high-risk populations or
endemic areas, where they can range from 0.02% to 50%,33
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they may reveal a seroconversion.30 The causes of indeter-
minate WB tests as well as their clinical meaning are still
not clear.33 The high proportion of indeterminate results is
a challenge worldwide and a serious problem for blood
banks because, depending on the reactivity profile, WB
may not be able to detect HTLV-1 or HTLV-2 infections.34
Molecular tests have been particularly useful for: 1) dis-
crimination between infection from Type 1 or Type 2 virus;
2) definition of dual infection (HTLV-1 and HTLV-2); 3) def-
inition of virus subtypes; 4) diagnosis in subjects with sus-
pected seroconversion; 6) resolution of cases with
seroindeterminate results;34 and 6) investigation of neona-
tal transmission, since the serologic tests in infants can
detect maternal antibodies.35
They are also used to quantify the level of HTLV infec-
tivity, or proviral load, which is an important risk marker
for the development of diseases associated with HTLV-1.
Indeed, the proviral load of HTLV-1 in peripheral blood is
higher compared to infection by other retroviruses, and
although the numbers vary greatly between infected indi-
viduals, the average proviral load in healthy carriers is sig-
nificantly lower than that of symptomatic patients.32,34,36
Real-time polymerase chain reaction (PCR) has been
preferentially employed over conventional PCR because of
its much higher sensitivity and specificity and low con-
tamination risk. It is also easy to use, gives rapid results,
and has proved to be a valid substitute for confirmatory
serologic tests. As HTLV does not have large quantities of
circulating viral RNA, plasma and serum are not suitable
for molecular diagnosis. Considering the HTLV tropism
for lymphocytes, whole blood is the biologic sample of
choice for the molecular diagnosis of infection.
TRANSMISSION ROUTES
HTLV-1 and HTLV-2 have similar transmission patterns.
Data on the length of the HTLV serologic window period
(WP) are determined by the sensitivity of the antibody
assay utilized and are reported in the 1992 study by Manns
and colleagues,37 which yielded a median 51-day WP but
was calculated with early-generation assays. Although in
the past 23 years there has been significant improvement
in assay sensitivity (third-generation assay) and the WP is
likely much shorter, to the knowledge of the authors there
are no recent data on this important topic. Interestingly, a
5-day noninfectious WP was deducted from the above-
mentioned 51-day WP in the 2009 study by Davison and
coworkers38 who, in the calculation to estimate the risk of
HTLV potentially infectious donations entering the UK
blood supply, used a 46-day WP. There are no reports of
infected individuals who had viral clearance.
The most important routes of HTLV-1 transmission
are mother to child (mainly through breastfeeding), sexual
intercourse, and transfusion of blood products containing
infected lymphocytes,37 which is the most efficient mode
of HTLV-1 transmission.39 Many reports have also docu-
mented its transmission through kidney, liver, marrow,
and lung transplant.40 The efficiency of the mother-to-
child transmission is estimated to be 20% and has been
correlated with individual variables such as HTLV-1 provi-
ral load, the concordance of HLA Class I type between
mother and child, and the duration of breastfeeding.41
The higher the exposure and proviral load, the higher the
risk of sexual transmission of both HTLV-1 and HTLV-2.
HTLV-2 shares some of these transmission routes but
intravenous (IV) drug use is its main mode of
transmission.42
EPIDEMIOLOGY
Prevalence in the general population
According to HTLV-1 prevalence, the world regions are
defined endemic (0.5 to 20%), at medium prevalence (0.1
to 0.5%), or not endemic (less than 0.1%; Fig. 1).43 How-
ever, at the moment, the global epidemiology of HTLVs is
still not clear. Prevalence data available are not accurate
due to several reasons such as: 1) the lack of data from
some parts of the world (Fig. 1); 2) prevalence overestima-
tion related to the low specificity of the early serologic
screening tests; 3) selective testing of population groups
(e.g., blood donors, pregnant women, and hospitalized
patients); and 4) an exceedingly heterogeneous distribu-
tion of the infection in some countries.42
In 2012, Gessain and Cassar44 reported that world-
wide there are 5 to 10 million HTLV-1 carriers, a lower
estimate in comparison to the previous one of 10 to 20
million. HTLV-1 is not a ubiquitous virus but is present
throughout the world with clusters of high endemicity
often close to areas where the virus is almost nonexistent.
In these foci, the HTLV-1 seroprevalence in adults is esti-
mated to be at least 1% to 2% but, in some specific clus-
ters, it can reach 20% to 40% in persons older than 50
years.44 Furthermore, there is a higher prevalence in
women.
Most epidemiologic data are based on serologic stud-
ies rather than on molecular tests. In 1986, Ishida and
Inuma45 clearly demonstrated that Japan was a high
endemic area for HTLV-1. Interestingly, from the begin-
ning, in Japan the geographic distribution of HTLV-1 car-
riers has been irregular and the greatest prevalence is
observed in southwestern Japan (Kyushu island and the
Okinawa archipelago).46 Almost contemporarily, US
researchers showed that the Caribbean and surrounding
regions were also endemic for HTLV-147 and ATL patients
were reported in the Caribbean community living in the
United Kingdom.48
Other endemic zones are some areas of Colombia
and French Guyana in South America, some parts of Sub-
Saharan Africa and the Middle East (Mashad region in
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Iran), and rare isolated clusters in Austral-Melanesia.44 In
Europe, only Romania seems an HTLV-1–endemic
region.44 Although the reason for this “ethnic distribution”
is not well understood, it is probably related to a “founder
effect” and a subsequent persistently high viral transmis-
sion rate in some populations.42
HTLV-2 is endemic in some African populations and
in Amerindian tribes from North, Central, and South
America, especially from Brazil, where some tribes show a
prevalence of 33%.49 It shares similar epidemiologic fea-
tures with HTLV-1: 1) the presence of population clusters
with high prevalence, 2) a higher prevalence in women, 3)
an increased prevalence rate with age, and 4) the same
routes of transmission. HTLV-2 is also present among IV
drug users, mainly in the United States and in Europe.43
Interestingly, in Amerindians the seroprevalence of HTLV-
1 and HTLV-2 ranges from 0.8% to 6.8% and from 1.4% to
57.9%, respectively.50
Prevalence in blood donors
The HTLV (mainly HTLV-1) prevalence in blood donor
populations ranges from 0% to approximately 5% to 6% in
some areas such as the Seychelles, some islands of South
Japan, and African countries.44 There are different sero-
prevalence rates for each continent. They range from
0%51-53 to 3.6%54 in Africa and from 0%55 to 1.5%56 in the
Americas (with a peak of 2% in some Caribbean islands).57
In Australia, the prevalence ranges from 0.001%58 to
0.3%59 and in Asia from 0%60-66 to 1.9%,67 while in Europe
it ranges from 0%68-70 to 2.12%.71 This last figure, reported
in the Netherlands in 1993, decreased to 0.41% in the
period 2001 to 2010;71 moreover, in 1994, Zaaijer and
coworkers72 showed a reduction of the seroprevalence
rate from 0.13% to 0.002% after WB confirmatory testing.
Furthermore, in Europe and Japan, most HTLV-infected
donors are HTLV-1 positive, whereas in the United States
a higher prevalence of HTLV-2 positivity is reported.36,43
Interestingly, a reduction of HTLV seroprevalence was
reported in some regions of the Americas: it decreased
from 0.0093% in 1990 to 0.0011% in 2010 in Canada,73
from 0.73% in 199174 to 0.24% in 2010 in Chile,75 and
from 0.6% in 1995 to 2000 to 0.1% in 2002 to 2008 in the
Minas Gerais Region (Brazil).76
Regarding HTLV incidence (per 100,000 donors/year),
it is closely connected with the local rate of prevalence in
this selected population and often estimated by mathe-
matical models. From 2007 to 2009, in Brazil, it was 3.59
per 100,000;77 from 2010 to 2012, in France, it was 0.4 per
100,000;42 from 1995 to 2001 and from 2008 to 2009, in the
United States, it was 0.239 and 0.304 per 100,000, respec-
tively.78,79 Interestingly, from 2005 to 2013, in Australia,
only one case of HTLV positivity among previously nega-
tive repeat donors was reported.80
PREVENTIVE MEASURES
The prevention of transfusion transmission of HTLVs can
be performed through testing blood donors. An anti-
HTLV-1 screening program of donated blood was intro-
duced in Japan in 1986.81 In 1988, the Centers for Disease
Control and Prevention recommended anti-HTLV-1
screening in the United States.82 In Canada, the
Fig. 1. HLTV-1 prevalence worldwide.43
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Caribbean, and the French Islands, blood screening for
HTLV-1 started in 1989.83 In the 1990s screening started in
France, Brazil, Australia, Denmark, Portugal, and Greece.39
In 1995, Sweden decided to screen only the first blood
donation for anti-HTLV-1 due to the almost nonexistent
local transmission of the virus.84 In 2002, the United King-
dom decided to test minipools (mixture of plasma from
blood donors) using an EIA.85 Finland and Norway inter-
rupted HTLV screening in 2007 and 2008, namely, 7 and
13 years after its introduction, respectively.86 The current
situation of HTLV screening in different countries is
reported in Fig. 2.
The results of hemovigilance and lookback studies
have provided evidence correlating the transmission of
HTLV with cellular blood component transfusion. The fac-
tors critical to the efficiency of transmission include the
number of contaminating WBCs. The HTLV proviral load
and/or the number of infected lymphocytes required to
cause infection and disease in recipients were addressed
by several studies carried out in animal models. In 1990,
the study by Kataoka and colleagues87 carried out in a rab-
bit model of HTLV-1 showed that 0.01 mL of HTLV-1–
infected blood containing 1.7 3 104 infected lymphocytes
was able to transmit the infection. Other studies were
aimed at setting up a rabbit model of clinical HTLV-1 dis-
ease and showed that reproducing an “ATL-like disease”
required a minimum of 1 3 108 cells by intraperitoneal or
IV injection.88-90 In addition, Kannian and colleagues91
Fig. 2. HTLV-1 and -2 screening in different countries (year 2015).39,81-86 *Only first-time donors screened.
HTLV AND TRANSFUSION SAFETY
Volume 56, January 2016 TRANSFUSION 253
recently showed that, in rabbits, HTLV-2 has a lower infec-
tion and replication efficiency in comparison to HTLV-1.
Experimental HTLV-1 infection, without disease develop-
ment, in nonhuman primates was demonstrated in sev-
eral monkey species inoculated with autologous (1 3
108)92,93 or homologous (1 3 107)93 infected cells. More
recently, development of clinical disease was reported
in pig-tailed macaques after inoculation with 5 3 106 to
103 106 mangabey cells infected with an HTLV-1 molecu-
lar clone.94
As far as HTLV-1 transmission in transfusion recipi-
ents is concerned, the early study by Okochi and Sato95
pointed out that more than 107 lymphocytes were neces-
sary for HTLV-1 infection through blood transfusion. A
1993 lookback study reported the transmission of HTLV-1
infection to a neonatal infant by transfusion of RBCs con-
taining an estimated number of 8 3 107 contaminating
WBCs.96
A 2004 evaluation of HTLV-1 removal by filtration of
blood components focused on provirus associated with
mononuclear cell (MNC) fraction and showed a reduction
of HTLV-1 (4.9 to 5.8 log) higher than that of WBCs.97 This
is consistent with the observation that commercially avail-
able filters remove more MNCs than granulocytes98-100
and efficiently retain T cells.101 The number of HTLV-1
copies detected in the MNC fraction was lower than 5 3
102 copies per filtered blood component.97 These data are
consistent with the findings that, in filtered blood compo-
nents, lymphocytes are 2% to 7% of residual WBCs98 and
T cells range from 1.68 3 102 to 4.09 3 104.101 Evidence of
the protective effect of leukoreduction was also produced
by the UK lookback study published in 2013, which
showed at least 93% reduction in the odds of transfusion-
transmitted HTLV in comparison to nonleukoreduced
blood components.102 Finally, a recent estimation of the
infectious viral load required for HTLV-1 transfusion
transmission and of the effectiveness of leukoreduction in
preventing transfusion-related infectivity claimed that the
transfer of more than 9 3 104 cells containing the HTLV-1
provirus is required to establish transfusion-transmitted
HTLV-1 infection and leukoreduction “decreases the num-
ber of HTLV-1–infected leucocytes below this level in most
blood components contaminated with HTLV-1.”103
Therefore, besides the legal requirements regarding
the highest amount of residual WBCs tolerated in blood
components (namely, fewer than 5 3 106 per unit as
required by the AABB,104 the US Food and Drug Adminis-
tration,105 and EU Recommendations106), a really effica-
cious leukoreduction of blood components is theoretically
able to prevent HTLV transfusion transmission, although
this has not been proven in humans. The current use of
universal leukoreduction in different countries is reported
in Fig. 3.107
PRTs can be exploited for PLT concentrates and the
irradiation of cellular blood components is an additional
tool to reduce the number of WBCs and the consequent
risk of seroconversion in immunosuppressed recipients.6,108
TRANSFUSION RISK
Blood transfusion is still a risk factor for HTLV-1 infection
for recipients in most African as well as other developing
countries that lack appropriate public health policies and
national blood systems. On the other hand, the residual
Fig. 3. Current use of universal leukoreduction.
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risk of transfusion-transmitted HTLV-1 in low-prevalence
countries is really minimal39 and, therefore, the risk of col-
lecting an infected donation that can be undetected by
screening tests is now estimated through mathematical
models. These models assume that the aforementioned
risk is almost completely due to donors in the acute infec-
tion WP and, therefore, is primarily dependent on the
HTLV incidence rate and the duration of the assay-
dependent WP.109
The estimated residual risk for HTLV-1 and -2 trans-
mission by blood transfusion is five per million donations
in Brazil (2007-2009),77 one per 3 million donations in the
United States (2000-2001),78 one per 7.6 million donations
in Canada (2007-2010),73 lower than one per million dona-
tions in Australia (2000/2003),110 and one per 20 million
donations in France (2010-2012, excluding overseas terri-
tories).42 Interestingly, the last estimate does not consider
the leukoreduction process, an extremely efficient preven-
tive measure for this intracellular pathogen. It is impor-
tant to underline that, when contextualizing transfusion
risks, estimates below the threshold of one in 1 million are
generally considered negligible.111
In 2012, in the Netherlands, Prinsze and Zaaijer71 esti-
mated that, without HTLV screening, on average 1.4
infected new donors and 0.5 infected regular donors per
year would donate blood, causing 0.8 to 0.007 cases of
HTLV disease per year. In 2014, in France, Laperche and
Pillonel42 claimed that if (in metropolitan France) the
antibody screening were abandoned, 104 transfusions of
HTLV-positive blood products per year would occur.
According to the authors’ figures this would result in
harmful consequences for one to two transfusion recipi-
ents per year without leukoreduction and for one recipi-
ent every 192 years in the event of 10% failure of filtration
procedures.
However, the probability of HTLV transmission is also
inversely proportional to the shelf life of (cellular) blood
components, which lose their contaminant power during
storage due to the decreasing viability of WBCs.42 The
highest risk is associated with the transfusion of RBCs.
The transmission rate of HTLVs ranges from 13% to 28% if
RBCs with a shelf life of 14 days are transfused and
increases to 25% to 75% when HTLV infected cellular
blood products of less than 6 days are used.112,113
There is no evidence that fresh-frozen plasma and
plasma-derived medicinal products transmit HTLV-1 and
-2, presumably because of the death of HTLV-infected
lymphocytes due to plasma freezing4 and fractionation
and for the fact that HTLVs are highly susceptible to inac-
tivation by the many methods currently used in plasma
fractionation.114 Isolated reports of HTLV-1–positive per-
sons with hemophilia can be found, but in most cases
negative results are obtained when HTLV-1 antibodies are
assayed in this group of patients.115
COST-EFFECTIVENESS AND
APPLICABILITY OF SCREENING TESTS
Several cost-effectiveness analyses of HTLV blood donor
screening have been carried out. These studies took into
account variables such as the prevalence and incidence of
infection in the population, the risks of transmission, the
mortality and morbidity of infected patients, and the
expected survival rate of recipients of infected blood
components.
According to the early study by Courouce and
coworkers116 in 1993, the cost per case of avoided contam-
ination in a 6-month period was 1.36 million French
francs. In the same year, in the United Kingdom, Brennan
and collaborators117 estimated that the minimum cost of
preventing a single transmission event was £30,000 while
the cost of preventing one case of HTLV-related disease
acquired through transfusion was £1.3 million.
In 1997, Sailly and colleagues118 estimated the cost-
effectiveness ratios of HTLV screening tests performed in
France using two efficiency measures: cost per prevented
seroconversion or positive blood donation detected
(6,137,346 francs) and cost per case of prevented leukemia
(34-307 million francs).
In 1998, in Sweden Tynell and colleagues84 showed
that the cost of preventing one HTLV transmission was
$440,000 when only new donors were screened. HTLV
screening was estimated to prevent one death every 200
years at a minimum cost of $36 million. They took into
account only the screening costs and did not perform sen-
sitivity analysis and discounting.119
In 2000, the study by Stigum and colleagues120
showed that when the HTLV prevalence among donors is
one per 100,000, the estimated cost of testing all new
blood donors for HTLV is US$9.2 million per life saved or
US$420,000 per quality-adjusted life-year (QALY) gained
by the intervention. When the prevalence among donors
is 10 per 100,000, the intervention will cost US$0.9 million
per life saved or US$41,000 per QALY gained.
In 2012, the results of 10 years of Dutch experience
showed that the cost of HTLV universal screening was
e996,000 per year, while it was estimated at e54,000 per
year if testing were limited to new donors.71 In the same
year, the poor cost-effectiveness of HTLV-1 and -2 anti-
body testing for all donations was confirmed by Borkent-
Raven and colleagues121 who showed that this strategy
incurs high costs per QALY gained.4 In fact, the incremen-
tal cost-effectiveness ratio for anti-HTLV-1 and -2 testing
is e45.2 million per QALY if all donations are tested, e2.23
million per QALY if only new donors are screened, and
e27 million per QALY if only blood components for pedi-
atric patients are tested.
The different costs reported in the aforementioned
studies are probably due to several factors: 1) wide ranges
of possible available tests, 2) different donor prevalence
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rates, 3) different duration of transfusion recipient follow-
up, 4) utilization of nonhomogeneous databases, and 5)
differences in health care settings. Moreover, in areas with
low prevalence, the cost-benefit of performing systematic
blood donor screening for HTLV is really questionable
also because many healthy donors with HTLV false posi-
tivity are unable to donate. In these areas, two factors play
a key role in determining the high cost-effectiveness ratio
for HTLV screening: 1) the low rate of morbidity and/or
mortality after HTLV transfusion-transmitted infection71
and 2) the length of incubation time.
Interestingly, the threshold for cost-effectiveness is
chosen rather arbitrarily.71 In the United States,
US$50,000 to US$100,000 per QALY is accepted, while this
figure is £30,000, e20,000, and $4100 in the United King-
dom, in the Netherlands,71 and in developing countries,122
respectively.
CONCLUSIONS
Although not all infected cellular blood products are able
to cause a disease in transfusion recipients,42 the impact
of HTLV-related pathologies can be serious and the prog-
nosis may be poor in terms of both survival and quality of
life. In addition, the financial costs for health systems may
be considerable. Therefore, the evaluation of prevalence
and incidence in the general population and in blood
donors, in countries where HTLV-1 is endemic, and the
constant monitoring of HTLV-1 infection in nonendemic
countries are of paramount importance to understand the
virus burden on human health and to guide the decision
process on preventive strategies.
Leukoreduction and freezing have proved to be effec-
tive in preventing HTLV transmission,97 and PRTs for
labile blood products might be an additional step toward
the safety of recipients but, at the moment, their use is
not generalized to all cellular blood products.123
Many countries have implemented systematic and
permanent universal screening of blood donors. However,
the HTLV antibody screening (probably maintained in
some countries under the precautionary principle, to take
into account political, regulatory, and public perception
issues, despite the high cost-effectiveness ratio) should be
adapted to the particular needs of differing local popula-
tions as one size does not fit all.
Since 1988, more than 200,000 HTLV false-positive
donors tested with licensed HTLV assays but without any
evidence of infection have been deferred and none of these
has been eligible for reentry, thus impacting on blood
product self-sufficiency.124 In developed nonendemic
countries (Fig. 1) that started the universal control of
donated blood (Fig. 2) and universal leukoreduction (Fig.
3), the current very low observed incidence and prevalence
among blood donors (reflecting a very low estimated risk
of an HTLV-1–positive donation entering the blood supply)
and the change in either the epidemiology of HTLV or the
length of the serologic WP should prompt further review of
the transmission risk and a possible change of the preven-
tion strategy.84 In these countries the systematic screening
of all donations should be questioned (and possibly inter-
rupted if already in use) after accurate evaluation of the
residual HTLV transfusion risk, while the leukoreduction of
cellular blood products should be maintained. However,
withdrawal of HTLV testing should be preceded by the
introduction of a permanent and strict control of leukore-
duction efficacy to detect failures that could seriously
impact on the safety of blood products. An additional and
probably cost-effective tool to reduce the risk of HTLV
transmission may be the implementation of the screening
of selected donor populations (e.g., first-time donors or
donors from endemic regions).116
The implementation of universal leukoreduction may
be an effective prevention strategy also in industrialized
nonendemic countries (Fig. 1) where blood donations are
not screened for HTLV (Fig. 2). In developing nonendemic
countries (Fig. 1), selective recruitment and/or screening
could be exploited as strategies to prevent HTLV transfusion
transmission. On the other hand, the suppression of anti-
HTLV screening in developed endemic countries (Fig. 1) is
not recommended; testing should be combined with leu-
koreduction until the efficiency of the latter procedure in
preventing HTLV transmission is unequivocally proven.
In developing countries where HTLV is endemic
(Fig. 1) and the residual risk of transfusion-transmitted
infection is greater, unfortunately, the costs of universal
testing and leukoreduction can be prohibitive and the
limited financial resources are often earmarked for the
prevention of other transfusion-transmitted infectious
diseases. In these countries, due to the higher virus circu-
lation and, therefore, higher seroconversion rates in repeat
blood donors, other strategies such as improving blood
donor selection process, counseling blood donor candi-
dates about HTLV infection and its risk factors to limit the
spread of the virus, and developing questionnaires vali-
dated and adapted to the local epidemiology125 might
play a key role.
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